CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 6216-A |

# Specialty Guideline Management Velsipity

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Velsipity | etrasimod |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Treatment of moderately to severely active ulcerative colitis (UC) in adults.

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

### Continuation Requests

Chart notes or medical record documentation supporting positive clinical response to therapy or remission.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a gastroenterologist.

## Coverage Criteria

### Ulcerative Colitis1

Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.

## Continuation of Therapy2,3

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

* Stool frequency
* Rectal bleeding
* Urgency of defecation
* C-reactive protein (CRP)
* Fecal calprotectin (FC)
* Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
* Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo score)

## Other

Member cannot use the requested medication concomitantly with immunomodulators, biologic drugs, or targeted synthetic drugs.

## Dosage and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

## References

1. Velsipity [package insert]. New York, NY: Pfizer Inc.; June 2024.
2. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomized, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023; 410(10383):1159-71.
3. Rubin DT, Ananthakrishnan AN, et al. 2019 ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413.
4. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158:1450-1461.